IDSA

The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!

Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR

Browse the best of 2025! The Editors-in-Chief of cidjournal.bsky.social, jidjournal.bsky.social & ofidjournal.bsky.social have selected a collection of outstanding articles from 2025. Explore research on long COVID, AMR, HIV, influenza, vaccines & more: https://bit.ly/49Xgge6

paulsaxmd.bsky.social

Thank you @bluntrochester.senate.gov for standing up for evidence-based vaccine policy and children’s health.

IDSA supports this letter from Members of Congress to RFK Jr. to reinstate the evidence-based childhood immunization schedule: bit.ly/4k52riB

The IDSA Foundation strengthens the infectious diseases workforce, advances research, and promotes equity in the fight against global ID threats.

Learn more: idsafoundation.org

When and How to Use Subcutaneous Antibiotics Subcutaneous administration of selected antibiotics provides a practical, safe alternative to intravenous therapy in patients with poor venous access, in o

Subcutaneous antibiotic administration is increasingly recognized as a valuable alternative to intravenous therapy in selected clinical contexts. In CID, authors summarize current clinical experience, PK/PD data, and technical aspects of subcutaneous infusion. https://bit.ly/3NB1jH5

IDSA is alarmed by reports of immigration enforcement activity occurring near health care settings. Health care professionals must be able to do their jobs without barriers that undermine patient trust or compromise care.

Our statement: https://bit.ly/3NKXjUA

Tampering With Evidence: Selective Silencing of Timely Public Health Data | Annals of Internal Medicine

The administration’s “anti-vaccine stance has interrupted the reliable flow of the data we need to keep Americans safe from preventable infections,” writes IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, in a new @annalsofim.bsky.social editorial. www.acpjournals.org/doi/10.7326/...

ID physicians see the devastating consequences of vaccine-preventable diseases every day, & now more than ever, families & clinicians need accurate information & evidence-based recommendations they can trust.

IDSA endorses AAP's 2026 childhood immunization schedule.

@ameracadpeds.bsky.social

🚨 #IMARI26 is SOLD OUT! 🚨

The inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation, hosted by ASM & IDSA and held Jan. 28–30, has officially reached capacity.

✅ Attendees: Plan your meeting here 👉 IMARI.org/program
👋 Not registered? We hope to see you at IMARI 2027!

JID for Clinicians: Looking to the future of infectious disease therapeutics Learn about advances in treating Shiga toxin-producing E. coli infections, the effectiveness of high-dose influenza vaccination and other research ready to inform clinical practice.

On IDSA’s & HIVMA’s Science Speaks blog: Read JID’s latest monthly roundup of papers relevant to clinicians, including articles on advances in treating Shiga toxin-producing E. coli infections, the effectiveness of high-dose flu vaccination and more. https://bit.ly/4jYbsK4

The skills of infectious diseases physicians are in high demand across public health. ID physician Do Young Kim, MD, D(ABMM) of City of Milwaukee Health Department shares why a career in public health is exciting, impactful and needed now more than ever.

Explore job paths in ID: bit.ly/49MHGmX

Tomorrow! Join IDSA’s Immunocompromised Host Community of Practice tomorrow, Jan. 26 at 11am ET for a timely webinar on influenza, RSV, parainfluenza and adenovirus, and the unique challenges these infections pose for immunocompromised patients.

Register: https://bit.ly/49zJfoe

HCV elimination in tribal communities: Embracing a syndemic approach Tribal nations in the U.S. are uniquely positioned to lead efforts to eliminate hepatitis C virus but also face persistent structural and social barriers that need attention.

On IDSA’s & HIVMA’s Science Speaks blog: Jorge Mera, MD, explores how tribal nations in the U.S. are uniquely positioned to lead efforts to eliminate hepatitis C virus in the next installment of the Health Equity Series. www.idsociety.org/science-spea...

Congrats to the 2025 class of Rising Leaders on completing IDSA’s online leadership development program! One of our largest cohorts yet, this group of ID and HIV practitioners strengthened leadership skills for impactful careers.

Know when 2026 applications open: idsa.tfaforms.net/f/Leadership...

Land your dream job in ID and HIV, and grow your network with IDSA’s new career center!

➡️ careercenter.idsociety.org (login or account creation required)

NEW features include search based on location, specialty and setting, and job market tracking.

The U.S. withdrawal from the World Health Organization is a shortsighted and misguided abandonment of our global health commitments.

Our statement: https://bit.ly/4jWGJgy

Day of Action — United For Cures

Today is the Day of Action. IDSA urges Congress to increase FY26 funding for medical research: https://unitedforcures.org/day-of-action

#SupportCures #FundMedicalResearch #CuresCantWait

What’s Hot This Year in ID Clinical Science 2025 This review covers notable public health trends and clinical trials covering a broad range of infectious diseases topics from October 2024 to September 202

The diversity and depth of clinical research in the field of infectious diseases in 2025 were impressive, bringing new antibiotics, technologies, and solutions.

A recent CID article reviews some of the most important clinical trials and trends in ID last year: https://bit.ly/4t0iXEH

IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, shares insights on new FDA-approved gonorrhea treatments on @ashasexualhealth.bsky.social's Sex+Health podcast.

Data, policy and practice: What will it take to make penicillin allergy evaluation and delabeling routine? Proposed legislation can help close gaps by aligning reimbursement, EHR integration and workforce training to make penicillin allergy delabeling routine across all care settings.

On IDSA’s & HIVMA’s Science Speaks blog: Kap Sum Foong, MD, FIDSA, explores how proposed legislation can help close gaps by aligning reimbursement, EHR integration and workforce training to make penicillin allergy delabeling routine across all care settings.
www.idsociety.org/science-spea...

Medical groups will ask court to block new CDC vaccine recommendations | CNN Six prominent medical associations say they will ask the courts to reverse the US Centers for Disease Control and Prevention’s new recommendations for what vaccines children should get.

IDSA and other prominent medical associations are calling on courts to reverse CDC’s new recommendations for what vaccines children should get.

Read more: www.cnn.com/2026/01/14/h...

Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers Postacute sequelae of COVID-19 (PASC) and postacute COVID-19 vaccination syndrome (PACVS) share significant symptom overlap, but differences in clinical pr

Post-acute sequelae of COVID-19 (long COVID) & post-acute COVID-19 vaccination syndrome present distinct challenges.

In @cidjournal.bsky.social, authors identify differences in presentation & distinguish immunologic biomarkers relevant to general clinical practice. https://bit.ly/4qRDWr0

Thanks to the incredible support of the ID community, the IDSA Foundation successfully met our Dec. 2025 matching gift challenge! Thank you to those that supported our work in 2025 and we look forward to building on this momentum in 2026.

Learn more: https://www.idsafoundation.org/our-impact

Learn the latest on travel-associated histoplasmosis during a CDC COCA Call this Thurs. Jan. 15 from 2-3pm ET.

Register: https://bit.ly/4jApqBA

Missed last month’s IDSA Fellows Case Conference? A recording is now available on the IDSA Academy!

Explore a complex ID case, hear expert insights, and learn alongside your peers: https://bit.ly/4sBU9m3

Impact of Candida Care Bundle Compliance on the Prognosis of Patients With Candidemia: A Multicenter Retrospective Cohort Study With Propensity Score Matching Analysis (2016–2023) AbstractBackground. Candidemia is a life-threatening infection with high mortality, and appropriate management is essential to improve patient outcomes. Th

Candidemia is a life-threatening infection with high mortality, and in-depth analyses of Candida Care Bundle compliance remain limited. In OFID, authors investigated the impact of bundle compliance on survival among patients with candidemia. https://academic.oup.com/ofid/article/13/1/ofaf790/8403191

We urge Congress to investigate why the schedule was changed and why credible scientific evidence was ignored.

Read the full sign-on letter: www.idsociety.org/news--public...

The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!

Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR

Tick-borne disease vaccines: What clinicians should know in 2026

On IDSA’s & HIVMA’s Science Speaks blog: Melvin Sanicas, MD, MSc, MScID, MBA, explores what’s on the horizon for vaccines for tick-borne diseases and shares clinical takeaways for 2026. www.idsociety.org/science-spea...

Regional variations of rates and determinants of drug resistance mutations in people failing first-line therapy for HIV-1: a substudy from the D2EFT phase 3b/4 clinical trial

In CID, authors evaluated the distribution of #HIV drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy in the D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) trial. https://bit.ly/3Ln8HFe